Filing summary
Entity and period: The supplied filing is Sevion Therapeutics, Inc.’s Form 10-Q for the quarter ended December 31, 2014 (fiscal second quarter), filed February 17, 2015. It is not identified as an Eloxx Pharmaceuticals filing; the request metadata and filing therefore do not match. Sevion changed its name from Senesco Technologies, Inc. in September 2014.
Financial performance and position
| Metric | Three months ended Dec. 31, 2014 | Six months ended Dec. 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $10.75 million | $15.93 million |
| Net loss | $10.75 million | $15.93 million |
| Loss per common share | $0.78 | $1.15 |
| Operating cash used | — | $3.47 million |
- Quarterly loss included an $8.12 million goodwill impairment. Six-month expenses also included a $2.29 million write-off of Factor 5A-related patents and a $0.67 million write-off of unused clinical-trial supplies. These are unusual, largely non-cash charges.
- Cash and cash equivalents were $2.11 million at December 31, down from $6.11 million at June 30, 2014. Working capital was negative $175,444. Management estimated cash would fund operations through at least March 31, 2015.
- Total liabilities were $6.61 million, including $2.55 million current liabilities and a $3.92 million deferred tax liability. The filing reports no off-balance-sheet arrangements and no borrowings or debt balance in the presented balance sheet.
- Accumulated deficit was $104.24 million. No meaningful operating margin is available because the company reported no revenue in the current quarter or six-month period.
Changes versus prior comparable periods
- Quarterly net loss increased $9.13 million, or 563.5%, from $1.62 million a year earlier, chiefly due to goodwill impairment and higher general and administrative and research and development costs.
- Six-month net loss increased $12.53 million, or 368.0%, from $3.40 million. The comparison also reflects goodwill and patent impairments, higher expenses, and Fabrus, Inc.’s inclusion after its May 2014 acquisition.
- Six-month revenue fell from $100,000 in 2013, which was an agricultural-license milestone payment, to zero in 2014. The company recognized no revenue in the current quarter.
- Cash used in operations rose to $3.47 million from $2.09 million in the prior-year half. There was no financing cash inflow in the 2014 half, compared with $6.87 million in the prior-year half.
Outlook, operations and risks
- Management expects continued losses for several years and says profitability timing cannot be predicted. The company needs additional capital and warned that financing may not be available on acceptable terms, or at all; failure to obtain funding could require program cuts, licensing, a sale, cessation of operations, or bankruptcy.
- The board suspended Factor 5A development after reviewing limited capital and Phase 1b/2a safety and efficacy results. Options include reformulation, partnering or sale, or discontinuation. Patient dosing was complete; a Grade 4 infusion reaction and a Grade 4 neutropenia were reported as dose-limiting toxicities.
- In December, Sevion temporarily reduced spending on its antibody program. It entered a collaboration with a Janssen affiliate to discover antibodies using its spatially addressed library. Terms include upfront and research-support payments; licensed candidates could yield milestone payments potentially totaling up to $125 million and low-single-digit royalties. The filing does not give a clear amount for the upfront payment.
- The New Jersey office was closed, and the University of Waterloo research agreement was terminated effective December 31, 2014. The company consolidated operations in San Diego. Contractual cash obligations totaled $1.64 million, including $1.08 million for employment and consulting agreements and $569,000 for facilities and leases.
- CEO Ronald A. Martell resigned effective January 8, 2015; separation terms remained under discussion. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Most important facts to verify
- Confirm issuer identity and reporting period: the filing names Sevion Therapeutics, Inc., not Eloxx Pharmaceuticals, Inc.
- Verify the company’s post-quarter financing, cash runway, and ability to meet obligations after the stated March 31, 2015 runway estimate.
- Review the Janssen collaboration’s confidential terms, payment amounts, option structure, and likelihood of milestone or royalty revenue.
- Assess Factor 5A’s clinical safety and efficacy findings and the board’s eventual decision on the program.
- Check the treatment of Martell’s severance and the June 30 balance-sheet total: the filing gives total assets of $33,344,828 but total liabilities and equity of $33,334,828, a $10 discrepancy.